Insulin degludec/liraglutide (IDegLira) (Xultophy®)

Assessment Status Rapid Review Complete
Drug Insulin degludec/liraglutide (IDegLira)
Brand Xultophy®
Indication For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.
Assessment Process
Rapid review commissioned 19/09/2016
Rapid review completed 17/10/2016
Rapid review outcome Full pharmacoeconomic assessment recommended at the submitted price.

The HSE has approved reimbursement; July 2019.